MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Graphic of two hands shaking under a red and purple light
Biotech

Novo inks $4.7B Akero buyout to bag late-phase MASH prospect

At $54 a share, the upfront deal value represents a 19% premium to Akero’s average stock price over the past 30 days.
Nick Paul Taylor Oct 9, 2025 8:21am
three triple doors opportunity cracked open ajar

89bio was left between a Roche and a hard place in buyout talks

Oct 2, 2025 9:55am
liver

Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug

Sep 18, 2025 5:02am
liver

FDA considers new liver trial endpoint, sending MASH shares up

Aug 28, 2025 11:25am
Person throwing piece of paper into full waste bin

Gilead culls last MASH program, 2 cancer assets

Aug 8, 2025 11:50am
Broom sweep clean

Novo Nordisk drops 2 obesity drugs during pipeline clearout

Aug 6, 2025 4:44am